Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 13/20 | 0.53 |
| ▸ | HRH1 | P35367 | 5/20 | 0.53 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30810181 | 0.89 | DRD2 (0.72) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL11852333 | 0.89 | DRD2 (0.72) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL11482447 | 0.87 | MAPT (0.55) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL11847914 | 0.87 | MAPT (0.53) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL11840635 | 0.87 | DRD2 (0.62) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL11848213 | 0.86 | MAPT (0.58) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL29358523 | 0.86 | MAPT (0.75) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL11846588 | 0.86 | MAPT (0.75) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL11854862 | 0.85 | MAPT (0.53) | MAPTSMN1; SMN2MAPK1POLBGAA | |
| SCHEMBL18310360 | 0.84 | MAPT (0.56) | MAPTSMN1; SMN2MAPK1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366852-A1 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication | N-GENE RESEARCH LABORATORIES, INC. | 2015-12-24 | — | — | US | disclosed |
| EP-2089032-B1 | A PHARMACEUTICAL COMPOSITION HAVING ANTIPSYCHOTIC, ANTIDEPRESSANT OR ANTIEPILEPTIC ACTIVITY WITH REDUCED SIDE EFFECT | N GENE RES LAB INC (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20100311719-A1 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication | N-GENE RESEARCH LABORATORIES, INC. | 2010-12-09 | — | — | US | disclosed |
| EP-2089032-A1 | A PHARMACEUTICAL COMPOSITION HAVING ANTIPSYCHOTIC, ANTIDEPRESSANT OR ANTIEPIIEPTIC ACTIVITY WITH REDUCED SIDE EFFECT | N-Gene Research Laboratories Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008053257-A1 | A PHARMACEUTICAL COMPOSITION HAVING ANTIPSYCHOTIC, ANTIDEPRESSANT OR ANTIEPIIEPTIC ACTIVITY WITH REDUCED SIDE EFFECT | N-GENE RESEARCH LABORATORIES INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20080108602-A1 | Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication | N-GENE RESEARCH LABORATORIES, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366852-A1 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication | GRM5, GRIK5, GRIN2A | MAPT 2917/4885SMN1; SMN2 2398/4885MAPK1 2776/4885 |
| US-20080108602-A1 | Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication | GRM5, GRIK5, GRIN2A | MAPT 2917/4885SMN1; SMN2 2398/4885MAPK1 2776/4885 |
| US-20100311719-A1 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication | GRM5, GRIK5, GRIN2A | MAPT 2917/4885SMN1; SMN2 2398/4885MAPK1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.